Eli Lilly (LLY) Stock: Olomorasib Shows 62% Response Rate in Lung Cancer Data

TLDR Eli Lilly (LLY) reported a 62% tumor response rate for olomorasib plus Keytruda and chemotherapy in first-line KRAS G12C lung cancer. Responses lasted a median of 14.5 months, and median progression-free survival was 11.6 months in the 77-patient study. Olomorasib plus Keytruda without chemotherapy had not reached median response duration or progression-free survival after 20.7 months. Randomized Phase 3 SUNRAY-01 results are expected in the first half of 2027. The data come from single-arm studies, so they do not yet prove olomorasib beats current treatments. Eli Lilly (LLY) shared new lung cancer data on Sunday. The company presented results for its experimental drug olomorasib at the 2026 European Society for Medical Oncology congress in Madrid. The release did not include a stock price move.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to CoinCentral.